Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPA1 | P27694 | 3/20 | 0.65 |
| ▸ | CACNA1G | O43497 | 3/20 | 0.63 |
| ▸ | CACNA1H | O95180 | 3/20 | 0.63 |
| ▸ | MALT1 | Q9UDY8 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | CNR1 | P21554 | 2/20 | 0.60 |
| ▸ | CNR2 | P34972 | 2/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.52 |
| ▸ | RELA | Q04206 | 1/20 | 0.52 |
| ▸ | BCL2 | P10415 | 1/20 | 0.51 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.51 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL695352 | 0.79 | RPA1 (1.00) | RPA1CACNA1GCACNA1HMEN1KMT2A | |
| SCHEMBL13239857 | 0.79 | RPA1 (0.70) | RPA1CACNA1GCACNA1HMALT1MEN1 | |
| SCHEMBL5527685 | 0.78 | CNR1 (0.44) | RPA1CACNA1GCACNA1HMALT1MEN1 | |
| SCHEMBL5518176 | 0.78 | CNR1 (0.46) | RPA1CACNA1GCACNA1HMALT1MEN1 | |
| SCHEMBL5529778 | 0.78 | CNR1 (0.52) | RPA1CACNA1GCACNA1HMALT1MEN1 | |
| SCHEMBL22748927 | 0.77 | RPA1 (0.77) | RPA1CACNA1GCACNA1HMALT1MEN1 | |
| SCHEMBL2487176 | 0.77 | RPA1 (0.77) | RPA1CACNA1GCACNA1HMALT1MEN1 | |
| SCHEMBL5523089 | 0.77 | CNR1 (0.53) | CACNA1GCACNA1HMALT1MEN1KMT2A | |
| SCHEMBL5531835 | 0.77 | CNR1 (0.51) | RPA1CACNA1GCACNA1HMALT1MEN1 | |
| Hydrochloric Acid SCHEMBL6315490 | 0.76 | RPA1 (0.62) | RPA1CACNA1GCACNA1HMALT1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110257146-A1 | Method of Treating Kcnq Related Disorders Using Organozinc Compounds | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-10-20 | — | — | US | claimed |
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| EP-4580679-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | Biohaven Therapeutics Ltd. (VG) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| US-20110257146-A1 | Method of Treating Kcnq Related Disorders Using Organozinc Compounds | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257146-A1 | Method of Treating Kcnq Related Disorders Using Organozinc Compounds | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257146-A1 | Method of Treating Kcnq Related Disorders Using Organozinc Compounds | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-10-20 | — | — | US | disclosed |
| WO-2007087424-A2 | METHOD OF TREATING KCNQ RELATED DISORDERS USING ORGANOZINC COMPOUNDS | THE JOHNS HOPKINS UNIVERSITY (US) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007087424-A2 | METHOD OF TREATING KCNQ RELATED DISORDERS USING ORGANOZINC COMPOUNDS | THE JOHNS HOPKINS UNIVERSITY (US) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257146-A1 | Method of Treating Kcnq Related Disorders Using Organozinc Compounds | KCNQ3, KCNQ1, KCNQ5 | RPA1 4882/4885CACNA1G 77/4885CACNA1H 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.